<DOC>
	<DOC>NCT01701063</DOC>
	<brief_summary>The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose adjustments if needed before Part B.</brief_summary>
	<brief_title>An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Males or females ages 3 to 17 years of age Chronic hepatitis C Hepatitis C virus genotype 1a or b at the Screening Visit Subject is judged to be in good health (besides HCV infection) in the opinion of the investigator. Signed informed consent form (ICF), and where appropriate, signed Assent Form History of or prior evidence of a medical condition associated with chronic liver disease other than HCV Body weight &lt;15 kg or &gt;90 kg Prior evidence of hepatic decompensation Contraindications to pegylated interferon/ribavirin (PegIFN/RBV) History or other evidence of severe retinopathy or clinically significant ophthalmological disorder History of nongenotype 1 HCV Participation in investigational drug study as described in Study Protocol Use of prohibited drugs within 7 days or 5 halflives before the first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>